Australia
Prescient Therapeutics is a clinical stage oncology company with a focus on developing personalized medicine approaches for cancer treatment. The company is involved in the development of both targeted and cellular therapies.
One of their prominent technologies is OmniCAR, a universal immune receptor platform that allows for controllable cell activity and multi-antigen targeting with a single cell product. This modular CAR system is based on technology licensed from Penn and Oxford University and is aimed at developing next-generation CAR-T therapies for various types of cancer.
Another significant technology is CellPryme-M, a novel technology that enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, thus improving persistence and the ability to target and penetrate tumors.
Additionally, the company is developing targeted therapies such as PTX-100, a compound designed to block an important cancer growth enzyme, and PTX-200, a novel PH domain inhibitor that targets an important tumor survival pathway, with a focus on specific cancer types.
Founded in 2014, Prescient Therapeutics operates in the biopharma, biotechnology, health care, health and wellness, and pharmaceutical industries. The company received a $3.00M post-IPO equity investment on 24 March 2014.
Apollomics
